Seller record · skinnyrx.com

SkinnyRx

Recorded September 2026 · Standard v1.1

Fails 2 of 8 criteria. S3, pharmacy identification: Eight rendered pages were read, covering the terms, privacy, questions and treatment surfaces, and each refers to a partner pharmacy or to 503A pharmacies as a category with no facility named. 1 more criterion also fails; see the table below.

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide as injections and tablets, alongside brand GLP-1 prescriptions. Its pages render only in a browser, and its address appears in the terms and the privacy policy rather than on its contact page.

Operating entity Lean Rx, Inc.

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	skinnyrx.com/contact
S2	Prescription gating	PASS	skinnyrx.com/intake
S3	Pharmacy identification	FAIL	skinnyrx.com/faq
S4	Compounding disclosure	PASS	skinnyrx.com
S5	Analytical documentation	FAIL	skinnyrx.com/products/semaglutide-injectable
S6	Business address	PASS	skinnyrx.com/terms
S7	Price disclosure	PASS	skinnyrx.com
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe questions page states that a licensed clinician reviews the medical intake and that a video visit may follow, and it names no individual prescriber.Source: skinnyrx.com/contact.

S2PASSThe order path was walked from the semaglutide page and reached a fifteen-step medical intake opening on a weight-loss goal, before any payment field.Source: skinnyrx.com/intake.

S3FAILEight rendered pages were read, covering the terms, privacy, questions and treatment surfaces, and each refers to a partner pharmacy or to 503A pharmacies as a category with no facility named.Source: skinnyrx.com/faq.

S4PASSA notice on the homepage states that compounded drugs are not Food and Drug Administration approved or evaluated for safety, effectiveness or quality.Source: skinnyrx.com.

S5FAILThe treatment pages state that partner pharmacies run third-party quality-control checks on every compounded lot, and no certificate or lot report is reachable from any page read.Source: skinnyrx.com/products/semaglutide-injectable.

S6PASSThe terms and the privacy policy both print a street address with a suite on N Street in Sacramento, California, while the contact page gives only an email address and a telephone number.Source: skinnyrx.com/terms.

S7PASSThe homepage prints three first-month figures with no account required: 99 dollars, 149 dollars and 199 dollars, each described as the first month.Source: skinnyrx.com.

S8PASSFDA warning letter 717989, February 2026, names Lean Rx, Inc. doing business as SkinnyRx at the Sacramento address this site prints, and cites claims of the same active ingredient as an approved drug. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injections and tablets, compounded tirzepatide injections and tablets, Wegovy, Foundayo.

Enforcement documents on file: 1 warning letter

FDA warning letter 717989, issued February 2026, to Lean Rx, Inc. dba SkinnyRxClaims on skinnyrx.com that compounded products give the same active ingredient as name-brand GLP-1 medications are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.